Loading…

Gabapentin Antinociception in Mice with Acute Herpetic Pain Induced by Herpes Simplex Virus Infection

The effects of systemic and local injections of gabapentin, a novel anticonvulsant agent, were tested on nociceptive behaviors in mice with acute herpetic pain. Transdermal infection with herpes simplex virus type-1 (HSV-1) produced nociceptive hypersensitivity of the infected hind paw to innocuous...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of pharmacology and experimental therapeutics 2001-02, Vol.296 (2), p.270-275
Main Authors: Takasaki, Ichiro, Andoh, Tsugunobu, Nojima, Hiroshi, Shiraki, Kimiyasu, Kuraishi, Yasushi
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 275
container_issue 2
container_start_page 270
container_title The Journal of pharmacology and experimental therapeutics
container_volume 296
creator Takasaki, Ichiro
Andoh, Tsugunobu
Nojima, Hiroshi
Shiraki, Kimiyasu
Kuraishi, Yasushi
description The effects of systemic and local injections of gabapentin, a novel anticonvulsant agent, were tested on nociceptive behaviors in mice with acute herpetic pain. Transdermal infection with herpes simplex virus type-1 (HSV-1) produced nociceptive hypersensitivity of the infected hind paw to innocuous (allodynia) and noxious mechanical stimulation (hyperalgesia) with von Frey filaments. Systemic administration of gabapentin (10–100 mg/kg, peroral) produced a dose-dependent inhibition of both allodynia and hyperalgesia; gabapentin (30–300 mg/kg) did not affect locomotor activity. Intrathecal injection of gabapentin (10–100 μg/animal) also attenuated dose dependently both nociceptive hypersensitivities. In contrast, intraplantar, intracisternal, and intracerebroventricular administration of gabapentin (10–100 μg/animal) had no effect on the HSV-1-induced nociceptive hypersensitivities. Pretreatment with naltrexone (1 mg/kg) inhibited antinociceptive effect of morphine (5 mg/kg), but not gabapentin (100 mg/kg). Repeated administration of morphine (5 mg/kg, four times) led to tolerance of antinociceptive action, whereas gabapentin (100 mg/kg, four times) had antinociceptive effect even after the forth administration. The present results suggest that gabapentin is effective in the treatment of acute herpetic pain without apparent adverse effects, and analgesic action of gabapentin is mainly mediated by actions on the spinal cord.
doi_str_mv 10.1016/S0022-3565(24)38784-1
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70631873</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022356524387841</els_id><sourcerecordid>70631873</sourcerecordid><originalsourceid>FETCH-LOGICAL-e294t-d661d36a529ecfd652bd0b8af6aa87299daede9e40276f5f6eb0aba3d366ae5a3</originalsourceid><addsrcrecordid>eNpFkUlPwzAQhS0EgrL8BJBPCA4BL4mTnFBVsUkgkFiuI8eeUKNsxAnQf49LWS4e2e-bJ888QvY5O-GMq9MHxoSIZKKSIxEfyyzN4oivkQlPBI8YZ3KdTP6QLbLt_StjPI6V3CRbnHPFFEsnBC91oTtsBtfQ6fJsjTPYDa5taHi6DRf64YY5nZpxQHqFfYeDM_ReB_W6saNBS4vFSvD0wdVdhZ_02fWjD3qJZmm1SzZKXXnc-6k75Oni_HF2Fd3cXV7PpjcRijweIqsUt1LpRORoSqsSUVhWZLpUWmepyHOr0WKOMROpKpNSYcHC92XoURoTLXfI4cq369u3Ef0AtfMGq0o32I4eUqYkz1IZwIMfcCxqtND1rtb9An4X8-80dy_zD9cjdHPd19q0VfuyAJErECBSFsCzFYhhrneHPXjjsAlrCU1mANs64AyWmcF3ZrAMBEQM35kBl181_ojY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70631873</pqid></control><display><type>article</type><title>Gabapentin Antinociception in Mice with Acute Herpetic Pain Induced by Herpes Simplex Virus Infection</title><source>Freely Accessible Journals</source><creator>Takasaki, Ichiro ; Andoh, Tsugunobu ; Nojima, Hiroshi ; Shiraki, Kimiyasu ; Kuraishi, Yasushi</creator><creatorcontrib>Takasaki, Ichiro ; Andoh, Tsugunobu ; Nojima, Hiroshi ; Shiraki, Kimiyasu ; Kuraishi, Yasushi</creatorcontrib><description>The effects of systemic and local injections of gabapentin, a novel anticonvulsant agent, were tested on nociceptive behaviors in mice with acute herpetic pain. Transdermal infection with herpes simplex virus type-1 (HSV-1) produced nociceptive hypersensitivity of the infected hind paw to innocuous (allodynia) and noxious mechanical stimulation (hyperalgesia) with von Frey filaments. Systemic administration of gabapentin (10–100 mg/kg, peroral) produced a dose-dependent inhibition of both allodynia and hyperalgesia; gabapentin (30–300 mg/kg) did not affect locomotor activity. Intrathecal injection of gabapentin (10–100 μg/animal) also attenuated dose dependently both nociceptive hypersensitivities. In contrast, intraplantar, intracisternal, and intracerebroventricular administration of gabapentin (10–100 μg/animal) had no effect on the HSV-1-induced nociceptive hypersensitivities. Pretreatment with naltrexone (1 mg/kg) inhibited antinociceptive effect of morphine (5 mg/kg), but not gabapentin (100 mg/kg). Repeated administration of morphine (5 mg/kg, four times) led to tolerance of antinociceptive action, whereas gabapentin (100 mg/kg, four times) had antinociceptive effect even after the forth administration. The present results suggest that gabapentin is effective in the treatment of acute herpetic pain without apparent adverse effects, and analgesic action of gabapentin is mainly mediated by actions on the spinal cord.</description><identifier>ISSN: 0022-3565</identifier><identifier>EISSN: 1521-0103</identifier><identifier>DOI: 10.1016/S0022-3565(24)38784-1</identifier><identifier>PMID: 11160607</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acetates - pharmacology ; Amines ; Analgesics - pharmacology ; Animals ; Behavior, Animal - drug effects ; Cyclohexanecarboxylic Acids ; Drug Tolerance ; Female ; gamma-Aminobutyric Acid ; Herpes Simplex - complications ; Herpes Simplex - virology ; Herpesvirus 1, Human ; Hyperalgesia - drug therapy ; Mice ; Mice, Inbred BALB C ; Motor Activity - drug effects ; Naltrexone - pharmacology ; Narcotic Antagonists - pharmacology ; Pain - drug therapy ; Pain - etiology</subject><ispartof>The Journal of pharmacology and experimental therapeutics, 2001-02, Vol.296 (2), p.270-275</ispartof><rights>2001 American Society for Pharmacology and Experimental Therapeutics</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11160607$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Takasaki, Ichiro</creatorcontrib><creatorcontrib>Andoh, Tsugunobu</creatorcontrib><creatorcontrib>Nojima, Hiroshi</creatorcontrib><creatorcontrib>Shiraki, Kimiyasu</creatorcontrib><creatorcontrib>Kuraishi, Yasushi</creatorcontrib><title>Gabapentin Antinociception in Mice with Acute Herpetic Pain Induced by Herpes Simplex Virus Infection</title><title>The Journal of pharmacology and experimental therapeutics</title><addtitle>J Pharmacol Exp Ther</addtitle><description>The effects of systemic and local injections of gabapentin, a novel anticonvulsant agent, were tested on nociceptive behaviors in mice with acute herpetic pain. Transdermal infection with herpes simplex virus type-1 (HSV-1) produced nociceptive hypersensitivity of the infected hind paw to innocuous (allodynia) and noxious mechanical stimulation (hyperalgesia) with von Frey filaments. Systemic administration of gabapentin (10–100 mg/kg, peroral) produced a dose-dependent inhibition of both allodynia and hyperalgesia; gabapentin (30–300 mg/kg) did not affect locomotor activity. Intrathecal injection of gabapentin (10–100 μg/animal) also attenuated dose dependently both nociceptive hypersensitivities. In contrast, intraplantar, intracisternal, and intracerebroventricular administration of gabapentin (10–100 μg/animal) had no effect on the HSV-1-induced nociceptive hypersensitivities. Pretreatment with naltrexone (1 mg/kg) inhibited antinociceptive effect of morphine (5 mg/kg), but not gabapentin (100 mg/kg). Repeated administration of morphine (5 mg/kg, four times) led to tolerance of antinociceptive action, whereas gabapentin (100 mg/kg, four times) had antinociceptive effect even after the forth administration. The present results suggest that gabapentin is effective in the treatment of acute herpetic pain without apparent adverse effects, and analgesic action of gabapentin is mainly mediated by actions on the spinal cord.</description><subject>Acetates - pharmacology</subject><subject>Amines</subject><subject>Analgesics - pharmacology</subject><subject>Animals</subject><subject>Behavior, Animal - drug effects</subject><subject>Cyclohexanecarboxylic Acids</subject><subject>Drug Tolerance</subject><subject>Female</subject><subject>gamma-Aminobutyric Acid</subject><subject>Herpes Simplex - complications</subject><subject>Herpes Simplex - virology</subject><subject>Herpesvirus 1, Human</subject><subject>Hyperalgesia - drug therapy</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Motor Activity - drug effects</subject><subject>Naltrexone - pharmacology</subject><subject>Narcotic Antagonists - pharmacology</subject><subject>Pain - drug therapy</subject><subject>Pain - etiology</subject><issn>0022-3565</issn><issn>1521-0103</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNpFkUlPwzAQhS0EgrL8BJBPCA4BL4mTnFBVsUkgkFiuI8eeUKNsxAnQf49LWS4e2e-bJ888QvY5O-GMq9MHxoSIZKKSIxEfyyzN4oivkQlPBI8YZ3KdTP6QLbLt_StjPI6V3CRbnHPFFEsnBC91oTtsBtfQ6fJsjTPYDa5taHi6DRf64YY5nZpxQHqFfYeDM_ReB_W6saNBS4vFSvD0wdVdhZ_02fWjD3qJZmm1SzZKXXnc-6k75Oni_HF2Fd3cXV7PpjcRijweIqsUt1LpRORoSqsSUVhWZLpUWmepyHOr0WKOMROpKpNSYcHC92XoURoTLXfI4cq369u3Ef0AtfMGq0o32I4eUqYkz1IZwIMfcCxqtND1rtb9An4X8-80dy_zD9cjdHPd19q0VfuyAJErECBSFsCzFYhhrneHPXjjsAlrCU1mANs64AyWmcF3ZrAMBEQM35kBl181_ojY</recordid><startdate>20010201</startdate><enddate>20010201</enddate><creator>Takasaki, Ichiro</creator><creator>Andoh, Tsugunobu</creator><creator>Nojima, Hiroshi</creator><creator>Shiraki, Kimiyasu</creator><creator>Kuraishi, Yasushi</creator><general>Elsevier Inc</general><general>American Society for Pharmacology and Experimental Therapeutics</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20010201</creationdate><title>Gabapentin Antinociception in Mice with Acute Herpetic Pain Induced by Herpes Simplex Virus Infection</title><author>Takasaki, Ichiro ; Andoh, Tsugunobu ; Nojima, Hiroshi ; Shiraki, Kimiyasu ; Kuraishi, Yasushi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e294t-d661d36a529ecfd652bd0b8af6aa87299daede9e40276f5f6eb0aba3d366ae5a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Acetates - pharmacology</topic><topic>Amines</topic><topic>Analgesics - pharmacology</topic><topic>Animals</topic><topic>Behavior, Animal - drug effects</topic><topic>Cyclohexanecarboxylic Acids</topic><topic>Drug Tolerance</topic><topic>Female</topic><topic>gamma-Aminobutyric Acid</topic><topic>Herpes Simplex - complications</topic><topic>Herpes Simplex - virology</topic><topic>Herpesvirus 1, Human</topic><topic>Hyperalgesia - drug therapy</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Motor Activity - drug effects</topic><topic>Naltrexone - pharmacology</topic><topic>Narcotic Antagonists - pharmacology</topic><topic>Pain - drug therapy</topic><topic>Pain - etiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Takasaki, Ichiro</creatorcontrib><creatorcontrib>Andoh, Tsugunobu</creatorcontrib><creatorcontrib>Nojima, Hiroshi</creatorcontrib><creatorcontrib>Shiraki, Kimiyasu</creatorcontrib><creatorcontrib>Kuraishi, Yasushi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Takasaki, Ichiro</au><au>Andoh, Tsugunobu</au><au>Nojima, Hiroshi</au><au>Shiraki, Kimiyasu</au><au>Kuraishi, Yasushi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gabapentin Antinociception in Mice with Acute Herpetic Pain Induced by Herpes Simplex Virus Infection</atitle><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle><addtitle>J Pharmacol Exp Ther</addtitle><date>2001-02-01</date><risdate>2001</risdate><volume>296</volume><issue>2</issue><spage>270</spage><epage>275</epage><pages>270-275</pages><issn>0022-3565</issn><eissn>1521-0103</eissn><abstract>The effects of systemic and local injections of gabapentin, a novel anticonvulsant agent, were tested on nociceptive behaviors in mice with acute herpetic pain. Transdermal infection with herpes simplex virus type-1 (HSV-1) produced nociceptive hypersensitivity of the infected hind paw to innocuous (allodynia) and noxious mechanical stimulation (hyperalgesia) with von Frey filaments. Systemic administration of gabapentin (10–100 mg/kg, peroral) produced a dose-dependent inhibition of both allodynia and hyperalgesia; gabapentin (30–300 mg/kg) did not affect locomotor activity. Intrathecal injection of gabapentin (10–100 μg/animal) also attenuated dose dependently both nociceptive hypersensitivities. In contrast, intraplantar, intracisternal, and intracerebroventricular administration of gabapentin (10–100 μg/animal) had no effect on the HSV-1-induced nociceptive hypersensitivities. Pretreatment with naltrexone (1 mg/kg) inhibited antinociceptive effect of morphine (5 mg/kg), but not gabapentin (100 mg/kg). Repeated administration of morphine (5 mg/kg, four times) led to tolerance of antinociceptive action, whereas gabapentin (100 mg/kg, four times) had antinociceptive effect even after the forth administration. The present results suggest that gabapentin is effective in the treatment of acute herpetic pain without apparent adverse effects, and analgesic action of gabapentin is mainly mediated by actions on the spinal cord.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>11160607</pmid><doi>10.1016/S0022-3565(24)38784-1</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-3565
ispartof The Journal of pharmacology and experimental therapeutics, 2001-02, Vol.296 (2), p.270-275
issn 0022-3565
1521-0103
language eng
recordid cdi_proquest_miscellaneous_70631873
source Freely Accessible Journals
subjects Acetates - pharmacology
Amines
Analgesics - pharmacology
Animals
Behavior, Animal - drug effects
Cyclohexanecarboxylic Acids
Drug Tolerance
Female
gamma-Aminobutyric Acid
Herpes Simplex - complications
Herpes Simplex - virology
Herpesvirus 1, Human
Hyperalgesia - drug therapy
Mice
Mice, Inbred BALB C
Motor Activity - drug effects
Naltrexone - pharmacology
Narcotic Antagonists - pharmacology
Pain - drug therapy
Pain - etiology
title Gabapentin Antinociception in Mice with Acute Herpetic Pain Induced by Herpes Simplex Virus Infection
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T01%3A21%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gabapentin%20Antinociception%20in%20Mice%20with%20Acute%20Herpetic%20Pain%20Induced%20by%20Herpes%20Simplex%20Virus%20Infection&rft.jtitle=The%20Journal%20of%20pharmacology%20and%20experimental%20therapeutics&rft.au=Takasaki,%20Ichiro&rft.date=2001-02-01&rft.volume=296&rft.issue=2&rft.spage=270&rft.epage=275&rft.pages=270-275&rft.issn=0022-3565&rft.eissn=1521-0103&rft_id=info:doi/10.1016/S0022-3565(24)38784-1&rft_dat=%3Cproquest_pubme%3E70631873%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-e294t-d661d36a529ecfd652bd0b8af6aa87299daede9e40276f5f6eb0aba3d366ae5a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=70631873&rft_id=info:pmid/11160607&rfr_iscdi=true